PTIX Key Statistics, Chart & Performance
The current stock price of PTIX is 0.74 USD. In the past month the price decreased by -59%. In the past year, price decreased by -89.55%.
PTIX Latest News, Press Relases and Analysis
PTIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.75B | ||
| AMGN | AMGEN INC | 15.61 | 183.80B | ||
| GILD | GILEAD SCIENCES INC | 15.11 | 153.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.81 | 122.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.03 | 85.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 829.5 | 55.89B | ||
| INSM | INSMED INC | N/A | 37.68B | ||
| NTRA | NATERA INC | N/A | 35.20B | ||
| BIIB | BIOGEN INC | 11.01 | 27.04B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.1 | 21.70B | ||
| INCY | INCYTE CORP | 17.31 | 21.82B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About PTIX
Company Profile
Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The firm has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The firm's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The firm's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The firm's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
Company Info
PROTAGENIC THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK 10010 US
CEO: Garo H. Armen
Employees: 1
Phone: 12129948200
PROTAGENIC THERAPEUTICS INC / PTIX FAQ
What does PROTAGENIC THERAPEUTICS INC do?
Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The firm has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The firm's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The firm's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The firm's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
Can you provide the latest stock price for PROTAGENIC THERAPEUTICS INC?
The current stock price of PTIX is 0.74 USD. The price decreased by -43.08% in the last trading session.
Does PTIX stock pay dividends?
PTIX does not pay a dividend.
How is the ChartMill rating for PROTAGENIC THERAPEUTICS INC?
PTIX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How many employees does PROTAGENIC THERAPEUTICS INC have?
PROTAGENIC THERAPEUTICS INC (PTIX) currently has 1 employees.
Can you provide the short interest for PTIX stock?
The outstanding short interest for PROTAGENIC THERAPEUTICS INC (PTIX) is 3.35% of its float.
PTIX Technical Analysis
PTIX Financial Highlights
Over the last trailing twelve months PTIX reported a non-GAAP Earnings per Share(EPS) of -8.1. The EPS increased by 54.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -178.31% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |